

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 22-23, 2022

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

She-Chia Chen, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Jorge A. Garcia, MD, FACP

(Chairperson)

Chief, Division of Solid Tumor Oncology
George & Edith Richman Distinguished Scientist Chair
Professor of Medicine and Urology
GU Medical Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Ranjana H. Advani, MD

(September 23 only)

Saul A. Rosenberg Professor of Lymphoma
Division of Oncology
Stanford University School of Medicine
Stanford, California

Pamela L. Kunz, MD

(September 22 only)

Associate Professor of Medicine (Oncology)
Division Chief, GI Oncology
Vice Chief
Diversity Equity and Inclusion, Medical Oncology
Yale School of Medicine and Yale Cancer Center
New Haven, Connecticut

Christopher H. Lieu, MD

Associate Professor of Medicine
Associate Director for Clinical Research
co-Director, Gastrointestinal Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado

Ravi A. Madan, MD

Senior Clinician, Genitourinary Malignancies Branch
Head, Prostate Cancer Clinical Research Section
Program Director, Physician-Scientist Early
Investigator Program
Center for Cancer Research
National Cancer Institute, National Institutes of Health
Bethesda, Maryland

David E. Mitchell

(Consumer Representative)

Founder, Patients for Affordable Drugs
Bethesda, Maryland

Jorge J. Nieva, MD

(September 22 PM session and September 23 only)

Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC) Norris
Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Ashley Rosko, MD

(September 22 Topic AM session only)

Associate Professor
Division of Hematology
Medical Director Oncogeriatric
The Ohio State University Comprehensive Cancer
Center
Columbus, Ohio

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 22-23, 2022

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) (cont.)

Anthony D. Sung, MD

(September 22 only)

Associate Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Albert L. Kraus, PhD

(Acting Industry Representative)

Global Regulatory Portfolio Lead – Oncology
Pfizer, Inc.
Guilford, Connecticut

TEMPORARY MEMBERS (Voting)

Andy I. Chen MD, PhD

(September 22 PM session and September 23 only)

Associate Professor, Center for Hematologic
Malignancies
Oregon Health & Science University
Portland, Oregon

Stephanie Y. Crawford, PhD, MPH

(September 22 PM session and September 23 only)

Executive Associate Dean for Faculty Affairs &
Strategic Initiatives
Professor, Department of Pharmacy Systems,
Outcomes and Policy
University of Illinois Chicago (UIC) College of
Pharmacy
Chicago, Illinois

John DeFlice, MD

*(Patient Representative for September 22 PM
session only)*

Albuquerque, New Mexico

Boris Freidlin, PhD, MS

(September 22 PM session and September 23 only)

Branch Chief, Biostatistics Branch
Division of Cancer Treatment & Diagnosis
National Cancer Institute
Bethesda, Maryland

Balazs Halmos, MD

(September 22 AM session only)

Associate Director for Clinical Science
Montefiore Einstein Cancer Center
Professor of Medicine
Albert Einstein College of Medicine
Bronx, New York

David Harrington, MA, PhD

Professor of Biostatistics (Emeritus)
Harvard T.H. Chan School of Public Health and
Dana-Farber Cancer Institute
Boston, Massachusetts

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 22-23, 2022

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Mary Kwok, MD

(September 22 PM session only)

Clinical Associate Professor,
Division of Hematology
University of Washington, Seattle, WA
Fred Hutchinson Cancer Center
Seattle, Washington

Michele Nadeem-Baker, MS

(Patient Representative for September 23 only)

Charlestown, Massachusetts

Grzegorz (Greg) S. Nowakowski MD

(September 22 PM session and September 23 only)

Professor of Medicine and Oncology
Deputy Director for Clinical Research
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota

James (Jim) G. Pantelas

(Patient Representative for September 22 AM session only)

Howell, Michigan

Mikkael A. Sekeres, MD, MS

(September 22 PM session and September 23 only)

Professor of Medicine
Sylvester Cancer Center
University of Miami
Miami, Florida

Katherine Scilla, MD, FACP

(September 22 AM session only)

Assistant Professor of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Anish Thomas, MD

(September 22 AM session only)

Investigator, Center for Cancer Research
Developmental Therapeutics Branch
National Cancer Institute
Bethesda, Maryland

Scott A. Waldman, MD, PhD, FCP, FAHA, FNAL, FASPET

(September 22 only)

Chair, Department of Pharmacology, Physiology, &
Cancer Biology
Samuel M.V. Hamilton Professor of Medicine
Jefferson (Philadelphia University + Thomas
Jefferson University)
Philadelphia, Pennsylvania

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 22-23, 2022

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Julia Beaver, MD

(September 22 AM session only)
Chief of Medical Oncology, OCE
Deputy Director (Acting), OOD
OND, CDER, FDA

Nicole Gormley, MD

(September 22 PM session and September 23 only)
Director
Division of Hematologic Malignancies II (DHM II)
OOD, OND, CDER, FDA

Bindu Kanapuru, MD

(September 22 PM session only)
Clinical Team Leader
DHM II, OOD, OND, CDER, FDA

Justin Malinou, MD

(September 22 AM session only)
Clinical Reviewer
DO2, OOD, OND, CDER, FDA

Alexandria Schwarsin, MD

(September 22 PM session only)
Clinical Reviewer
DHM II, OOD, OND, CDER, FDA

Marc R. Theoret, MD

(September 22 PM session and September 23 only)
Deputy Center Director, OCE
Supervisory Associate Director (Acting)
OOD, OND, CDER, FDA

Harpreet Singh, MD

(September 22 AM session only)
Director
Division of Oncology 2 (DO2)
OOD, OND, CDER, FDA

Nicole Drezner, MD

(September 22 AM session only)
Clinical Team Lead
DO2, OOD, OND, CDER, FDA

Nicholas Richardson, DO, MPH

(September 23 only)
Clinical Team Leader
DHM II, OOD, OND, CDER, FDA

Jeanne Fourie Zirkelbach, PhD

(September 22 AM session only)
Team Lead, Clinical Pharmacology
Division of Cancer Pharmacology 2
Office of Clinical Pharmacology
Office of Translational Sciences, CDER, FDA

Deepti Telaraja, MD

(September 23 only)
Clinical Reviewer
DHM II, OOD, OND, CDER, FDA